Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer

Conditions

• Prostate Cancer

Eligibility Criteria

Sex

MALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Hospital based follow up — OTHER
  Exclusively hospital led follow up, face-to-face or remotely by the specialist treating team.
• Primary care based follow up — OTHER
  After the initial hospital follow up, patients are discharged and exclusively managed by (non-specialist) general practices (GP or nurse led) in face-to-face or remote appointments, with hospital referral as necessary.
• Planned shared care follow up — OTHER
  An ongoing combination of general practice and hospital management
• Self-management — OTHER
  After initial hospital follow up, patients are discharged and managed remotely, with no scheduled review. A tracking system monitors prostate-specific antigen (PSA) tests performed in primary care or secondary care. Patients access support workers for remote consultation to discuss symptoms and request further specialist management as required.

Study Details

Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.

Key Dates

First listed

Dec 4, 2025

Start date

Oct 31, 2026

Status verified

Apr 2026

Primary completion

Jul 31, 2027

Completion

Jul 31, 2027

Study Design

Enrollment

100,000 participants (estimated)

Arms

• Arm: Hospital based follow up
  Exclusively hospital led follow up, face-to-face or remotely by the specialist treating team.
• Arm: Primary care based follow up
  After the initial hospital follow up, patients are discharged and exclusively managed by (non-specialist) general practices (GP or nurse led) in face-to-face or remote appointments, with hospital referral as necessary.
• Arm: Planned shared care follow up
  An ongoing combination of general practice and hospital management
• Arm: Self-management
  After initial hospital follow up, patients are discharged and managed remotely, with no scheduled review. A tracking system monitors prostate-specific antigen (PSA) tests performed in primary care or secondary care. Patients access support workers for remote consultation to discuss symptoms and request further specialist management as required.

Primary Outcome Measure

Safety and clinical effectiveness defined by treatment for cancer recurrence [ Time Frame: At 3 years following end of initial radical surgery or radiotherapy or focal therapy ]

Central Contacts

• Diana Johnson, BSc (Hon)
  +44 (0) 1224 438144
  [email protected]

Find similar trials

Related Studies

• Collection of Blood From Patients With Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
  Enrolling By Invitation · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey